NCT07080619View on ClinicalTrials.gov

SC-101 in Subjects With Advanced NECTIN4-Amplified Cancers

PHASE2Not yet recruitingINTERVENTIONAL

Enrollment

120

Participants

Timeline

Start Date

September 20, 2025

Primary Completion Date

July 30, 2027

Study Completion Date

December 30, 2027

Conditions

TNBC - Triple-Negative Breast CancerHR+ Breast Cancer

Interventions

DRUG

SC-101

Receive 7.5 mg/m² of SC-101 intravenously once weekly (QW).

All Listed Sponsors

lead

Tianjin ConjuStar Biologics Co., Ltd.

INDUSTRY